Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Flucelvax Trivalent Influenza Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

NCT02860039
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions
Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
3 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

NCT00782431
View directory record Official record
Conditions
Influenza
Interventions
Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531
View directory record Official record
Conditions
Plasma Cell Neoplasm
Interventions
Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

NCT01695733
View directory record Official record
Conditions
Neoplasms
Interventions
trivalent influenza vaccine
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate Immune Responses of FluMist®

NCT00461981
View directory record Official record
Conditions
Influenza Vaccine
Interventions
TIV, Trivalent Inactivated Influenza Virus Vaccine, FluMist, Influenza Virus Vaccine Live
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
12 Months to 35 Months
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Not listed Not applicable Interventional

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723
View directory record Official record
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

NCT00677820
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

NCT00980005
View directory record Official record
Conditions
Influenza
Interventions
GSK investigational vaccine GSK1557482A, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
3 Years to 17 Years
Enrollment
2,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Benton, Arkansas • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456
View directory record Official record
Conditions
Influenza, Human, Transplantation Infection
Interventions
influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

NCT00388583
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462
View directory record Official record
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Safe Administration of Flu Vaccine to Egg Allergic Children

NCT01264601
View directory record Official record
Conditions
Egg Allergy
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women

NCT01173211
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
5
States / cities
St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

NCT03179761
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

NCT03282240
View directory record Official record
Conditions
Influenza
Interventions
QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
2,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
36
States / cities
Anaheim, California • Redding, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Half-Dose Flu Vaccine Study in Healthy Adults

NCT00006146
View directory record Official record
Conditions
Influenza
Interventions
Approved influenza virus vaccine.
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
6
States / cities
Torrance, California • College Park, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

NCT00662272
View directory record Official record
Conditions
Influenza
Interventions
Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
Biological
Lead sponsor
Colby Pharmaceutical Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Sep 30, 2026, 5:41 PM EDT